Sisram Medical Ltd. announced that the phase IIb clinical result on submental fat reduction (the "Phase IIb Clinical Result") of JS-001, a product licensed to Tianjin JuveStar Biotechnology Company Ltd. (an associate company of the Company), has reached its primary endpoint. The Phase IIb Clinical Result showed that (i) on the 84th day after a single injection of JS-001, the volume of submental fat of the clinical trial participants was reduced by 15% on average; and (ii) most of
the adverse effects were local (mainly affecting the area of injection) and transient. Pre-clinical and clinical studies of JS-001 both demonstrate that JS-001 can induce adipocyte decay and reduce thickness of fat layer, and therefore it can be used for body contouring. A multi-regional phase III clinical trials (including mainland China) of JS-001 will be initiated in late 2022 to further verify its safety and efficacy.